After nearly three months lacking a permanent company head, stem cells researcher Aastrom Biosciences (NASDAQ: ASTM ) announced Wednesday that it has finally settled upon a Chief Executive Officer to replace the one it lost in December.
Back in December, Aastrom CEO Tim Mayleben left the company to take a different CEO job at his previous company,�privately held Esperion Therapeutics, thus initiating a short game of musical chairs at Aastrom.
First, Chief Commercial Officer Dan Orlando was forced to keep the CEO's seat warm for a new permanent boss. Then, on Wednesday, the company confirmed that it has hired former Eli Lilly (NYSE: LLY ) exec Dominick C. Colangelo to serve as its CEO. Most recently, Colangelo served as CEO of biotech start-up Promedior, for more than three years.
Strangely, Aastrom shares appear to have begun "reacting" to the news before it was announced, rising 7.5% in Wednesday trading, to close at $1.29.
��More Expert Advice from The Motley Fool
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.
No comments:
Post a Comment